The pr..." /> Online hot pursuit news capital market
29 Apr, EOD - Indian

SENSEX 80288.38 (0.09)

Nifty 50 24335.95 (0.03)

Nifty Bank 55391.25 (-0.07)

Nifty IT 35920.4 (1.23)

Nifty Midcap 100 54587.95 (0.27)

Nifty Next 50 64892.35 (-0.23)

Nifty Pharma 21676.65 (-1.06)

Nifty Smallcap 100 16738.7 (0.37)

29 Apr, EOD - Global

NIKKEI 225 35839.99 (0.38)

HANG SENG 22008.11 (0.12)

S&P 5594.5 (0.53)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(19 Feb 2025, 14:42)

Morepen Laboratories gains after arm incorporates new subsidiary

Morepen Laboratories rallied 3.95% to Rs 51.87 after the board of directors of Dr. Morepen (DML), a wholly owned subsidiary of the company has approved the formation of a new subsidiary on 19 February 2025.


The new entity will be named "QUICK MED" or any other name as approved by the Central Registration Centre, Ministry of Corporate Affairs.

The proposed company will operate in the pharmaceutical sector, with a focus on the 'Online Retail Pharmacy' business. This move aligns with DML's inorganic growth strategy to cater to the increasing demand in the online pharmacy market.

DML will contribute Rs 80,000 in cash, representing 80% of the initial subscription, by acquiring 8,000 equity shares at Rs 10 each in the proposed company. As a result, Morepen Laboratories will indirectly hold 80% of the shares in this new step-down subsidiary through DML.

Upon its incorporation, the proposed company will become a step-down subsidiary of Morepen Laboratories. The company received this update from DML on 19 February 2025.

Morepen Laboratories is a leading player in the pharmaceutical and healthcare industry. Over the past four decades, Morepen has carved out a significant niche in the medical devices and Active Pharmaceutical Ingredients (API) segments. The company’s API business is renowned for its high-quality products and extensive global reach. The company exports a substantial portion of its API products, catering to the needs of numerous international markets. Morepen holds a leadership position in the export of 6 key API products: loratadine, melukast, desloratadine, atorvastatin, and fexofenadine.

The company’s consolidated net profit fell 16.6% to Rs 26.69 in Q3 FY25 as against Rs 31.99 crore in Q3 FY24. However, revenue from operations rose 1.9% to Rs 452.78 crore in the quarter ended 31 December 2024.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +